Journal article
Antifungal antibiotics and breakthrough bacteremias
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol.32(11), pp.1538-1539
06/01/2001
DOI: 10.1086/320534
PMID: 11340523
Abstract
Patients with fever and neutropenia are at high risk for infection ( approximately 50%) and bacteremia ( approximately 20%). As a result, most are treated with antibacterial prophylaxis until their absolute neutrophil count exceeds 500 cells/mm(3) and their temperature returns to normal. The 1997 guidelines of the Infectious Diseases Society of America suggested 1 of 3 regimens: vancomycin plus ceftazidime, monotherapy with ceftazidime or imipenem (possibly cefepime or meropenem), or dual therapy with an aminoglycoside plus an antipseudomonal beta-lactam.
Details
- Title: Subtitle
- Antifungal antibiotics and breakthrough bacteremias
- Creators
- Richard P Wenzel - Department of 1Internal Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298-0663, USA. rwenzel@hsc.vcu.eduChris GenningsMichael B Edmond
- Resource Type
- Journal article
- Publication Details
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol.32(11), pp.1538-1539
- DOI
- 10.1086/320534
- PMID
- 11340523
- NLM abbreviation
- Clin Infect Dis
- ISSN
- 1058-4838
- eISSN
- 1537-6591
- Publisher
- United States
- Language
- English
- Date published
- 06/01/2001
- Academic Unit
- Infectious Diseases; Internal Medicine
- Record Identifier
- 9983905526102771
Metrics
36 Record Views